Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,671 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06946745Recruiting
Studying IBI363 combo for advanced colorectal cancer
This study tests a new combination therapy (IBI363 with other drugs) for advanced colorectal cancer that is pMMR/MSI-L/MSS. It aims to understand how the immune system around the tumor changes during treatment.
BeijingAges 18–75 - NCT06808971RecruitingPhase 2
Perioperative drug combo for advanced stomach cancer
This study tests a combination of four drugs given before and after surgery for a type of stomach or throat-stomach cancer that can be removed. The drugs are adebrelimab (immunotherapy), nab-paclitaxel, oxaliplatin, and tegafur. The goal is to see if this combination works better than standard treatments.
BeijingAges 18–75 - NCT06750484RecruitingPhase 2
Testing trastuzumab deruxtecan in HER2-zero breast cancer
This trial tests a new drug called trastuzumab deruxtecan (a targeted antibody-drug combination) for people with advanced breast cancer that never showed any HER2 protein (HER2-zero). The goal is to see if it can shrink tumors and improve outcomes for those who have already had standard treatments.
New Haven, ConnecticutAges 18 years+ - NCT06622486RecruitingPhase 1/Phase 2
EGL-001 for advanced solid tumors after immunotherapy
This trial tests a new drug called EGL-001 for people with advanced solid tumors that have already been treated with immunotherapy. The goal is to see if the drug is safe and effective against cancer that has not responded to other treatments.
DijonAges 18 years+ - NCT06630793Recruiting
Comparing types of radiation for anal cancer
This study compares standard radiation (IMRT) with a newer, more precise type (IMPT) both given alongside chemotherapy for anal cancer. It aims to see which is better at controlling cancer and reducing side effects.
Mumbai, MaharashtraAges 18–80 - NCT06572514RecruitingPhase 1/Phase 2
Lower radiation after chemo-immunotherapy for head and neck cancer
This trial tests if giving less radiation than usual is safe and effective for certain head and neck cancers after initial treatment with chemotherapy and immunotherapy. It aims to reduce side effects while still controlling the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06475131RecruitingPhase 1
Study of BL-B16D1 for advanced solid tumors
This trial tests a new drug called BL-B16D1 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if this drug is safe and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT06246071RecruitingPhase 1
TYK-00540 for adults with solid tumors
This trial tests a new drug, TYK-00540, for people with solid tumors that have not responded to or cannot tolerate standard treatments. It also looks at specific types of breast and ovarian cancer.
HefeiAges 18 years+ - NCT06120803RecruitingPhase 2
Esomeprazole for preventing radiation-induced esophagitis
This study tests whether a common heartburn medicine (esomeprazole) can help prevent or reduce painful swallowing caused by radiation for lung cancer. If you have stage 3 non-small cell lung cancer and are getting chemo and chest radiation, you may be able to join.
Chicago, IllinoisAges 18 years+ - NCT05923008RecruitingPhase 1/Phase 2
Study of IBI130 for advanced solid tumors
This trial tests IBI130 in people with unresectable, locally advanced, or metastatic solid tumors (cancers that can’t be fully removed by surgery or have spread). It may help find whether the drug is safe and can work against these cancers.
Birtinya, QueenslandAges 18 years+ - NCT05866692RecruitingPhase 1
First-in-human capsule for advanced solid tumors
This Phase 1 study tests a new oral capsule (TY-2699a) in people with advanced or metastatic solid tumors that have limited treatment options. It will look for the safest dose and whether the drug can shrink tumors, especially in certain genetic/biomarker patterns.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05738434RecruitingPhase 2
Testing immunotherapy plus targeted drug with short chemo for esophagus cancer
This Phase 2 study tests whether combining camrelizumab (immunotherapy) and apatinib (a targeted drug) with short-course chemotherapy can control advanced esophageal squamous cell carcinoma. It may help by improving cancer response and slowing disease growth if you’re eligible and haven’t had prior whole-body (systemic) anti-cancer treatment.
Zhengzhou, HenanAges 18–75 - NCT05715931RecruitingPhase 2
Surgery chemotherapy plus anti-HER2 and anti–immune therapy for HER2 stomach cancer
This Phase 2 trial tests adding chemotherapy plus trastuzumab and toripalimab around the time of surgery for HER2-positive, locally advanced stomach or esophagus-stomach junction cancer. It aims to shrink the cancer and reduce the chance it comes back by attacking it through more than one pathway.
Hangzhou, ZhejiangAges 18–80 - NCT05471856RecruitingPhase 1
Test different doses of cancer drugs with ezabenlimab
This Phase 1 trial tests how different doses of a study drug (BI 1703880) work and how safe they are when given with ezabenlimab for advanced solid tumors. It’s for people whose cancer can’t be removed with surgery and who have tried standard treatments or can’t get them.
Los Angeles, CaliforniaAges 18 years+ - NCT05617859RecruitingPhase 2
Lenvatinib treatment for advanced bone or soft tissue sarcoma
This trial tests lenvatinib to shrink or control advanced bone or soft tissue sarcoma that can’t be safely treated with surgery. You may be eligible if your cancer has measurable spots and you’ve had specific prior drug treatments without a durable response.
Zhengzhou, HenanAges 10–70 - NCT05464082RecruitingPhase 2
Collect tumor samples to guide early breast cancer recurrence care
This Phase 2 study tests a “precision” approach using tumor sample testing to help predict, prevent, and treat early metastatic recurrence in triple-negative or hormone-receptor–low, HER2-negative breast cancer. If you qualify, you’ll be asked to provide tumor tissue before (or in place of) standard chemotherapy, so researchers can learn which tumor features matter most.
Salt Lake City, UtahAges 18 years+ - NCT04859465RecruitingPhase 2
Paclitaxel plus doxorubicin for advanced, unresectable angiosarcoma
This Phase 2 trial tests a chemotherapy combination (paclitaxel and liposomal doxorubicin) for people with advanced angiosarcoma that cannot be removed by surgery. It is meant for cases where standard treatment either did not work or was too hard to tolerate, and it aims to shrink tumors and control the disease.
Guangzhou, GuangdongAges 18–70 - NCT04819243RecruitingPhase 2
Test a BRCA-targeted drug plan for advanced ER-positive breast cancer
This Phase 2 study tests how well a treatment plan using palbociclib followed by talazoparib (and possibly atezolizumab) works in certain people with advanced ER-positive breast cancer. It may help by targeting cancer biology linked to BRCA/HRD changes and by strengthening how the cancer is controlled.
Seoul, Gannam-guAges 19 years+ - NCT06730659RecruitingPhase 1
CHT101 for CD70-positive advanced solid tumors
This study tests a new drug called CHT101 for people with advanced solid tumors that have a specific protein (CD70) on the cancer cells. It may be an option if standard treatments have already been tried and failed.
TianjinAges 18–70 - NCT03772561RecruitingPhase 1
Testing AZD5363, olaparib, and durvalumab for advanced solid cancers
This Phase 1 trial tests a combination of three medicines to shrink or control advanced solid tumors that are progressing or no standard options exist. It mainly focuses on safety and early signs of how well the treatment works.
Singapore, SingaporeAges 21–99 - NCT05533983Recruiting
Stool transplant plus nivolumab for advanced solid cancers
This study tests whether transferring stool microbiome (“FMT,” stool transplant) along with nivolumab can improve outcomes in people with advanced solid cancers that kept worsening even after anti–PD-1/PD-L1 treatment. It also looks at stool and blood changes to understand why the treatment might work.
SeoulAges 19 years+ - NCT04109131Recruiting
Study platform for brain metastases in solid cancers
This trial studies people with solid tumors that have spread to the brain (including the brain lining) to help researchers learn what works and how best to treat it. You may be asked for blood/tissue samples and a procedure to collect spinal fluid when brain metastases are diagnosed.
AnderlechtAges 18 years+ - NCT07671534RecruitingPhase 2
Metronomic chemotherapy with gemcitabine, mitomycin C, and thalidomide for advanced solid tumors
This trial tests a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in a low, frequent 'metronomic' schedule to treat advanced solid tumors that have already been treated. The goal is to see if this approach can slow or stop tumor growth with fewer side effects.
Santa Monica, CaliforniaAges 18 years+ - NCT07118527RecruitingPhase 3
New drug combo for untreated advanced stomach cancer
This trial tests a new combination of an anti-HER2 drug (SHR-A1811) plus chemotherapy and an immunotherapy (adebrelimab) for people with untreated advanced stomach cancer. It aims to see if this combination works better than standard treatment.
Shenyang, LiaoningAges 18–75
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,671 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.